Trial Profile

Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary) ; Linvoseltamab (Primary) ; Linvoseltamab (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms LINKER-MM4
Sponsors Regeneron Pharmaceuticals

Most Recent Events

06 Feb 2026 Planned number of patients changed from 132 to 149.
08 Dec 2025 Results published in the Media Release
07 Dec 2025 According to Regeneron Pharmaceuticals media release, data from this study were presented at the American Society of Hematology (ASH) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com